跳至主要内容
临床试验/NCT00521716
NCT00521716暂停不适用

A Single Arm, Uni-Center, Prospective Clinical Investigation to Evaluate Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation

OrthoMediTec1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
发起方
入组人数
20
试验地点
1
主要终点
The safety endpoint is measure by paucity incidence of treatment related major complications.

研究概览

简要总结

The purpose of this study is to determine the safety and efficacy of using WaisFix100i device for Intracapsular Femoral Fracture Fixation.

详细描述

Fractures of the neck of the femur represent an estimated cost to society that exceeds ten billion dollars annually in the USA only.

Fractures have been treated with immobilization, traction, amputation, and internal fixation throughout history. Immobilization by casting, bracing, or splinting a joint above and below the fracture was used for most long bone fractures.

Several studies have suggested that reduction and fixation of an Intracapsular fracture of the hip with multiple pins or screws is associated with a lower rate of morbidity and mortality than treatment with prosthetic replacement. With improved methods of fixation and a tendency toward earlier weight-bearing, internal fixation is believed to be a better mode of treatment for younger, more active patients.

On the other hand, the internal fixation procedure may result with number of possibilities for serious complications and biomechanical disadvantages, leading to the device failure. This led to a growing tendency to prefer total or partial hip replacement as the common treatment for intracapsular fracture, although the internal fixation is the favorable procedure in the professional literature.

OrthoMediTec has developed the WaisFix100i device, a new concept for Intracapsular Femoral Fracture Fixation and bone grafting using minimally invasive procedures. The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male/Female with Intracapsular femoral fracture type Garden I-II and several III.
  • Subject able to comprehend and give informed consent for participation in this study.

排除标准

  • Known active infectious disease.
  • Terminal diseases
  • Patients in high risk and/or acute cardio-vascular disease.
  • Known cognitive disorder, psychiatric and/or neurological disease
  • Physician objection.
  • Age under 50 or above
  • Concurrent participation in any other clinical study
  • Patients cannot understand or not willing to sign the informed consent.

结局指标

主要结局

The safety endpoint is measure by paucity incidence of treatment related major complications.

时间窗: Study duration

次要结局

  • Efficacy endpoint is measure by the following: 1. A subject is scored a success if he had no revision surgery, hemi- arthroplasty or total hip replacement surgery by 12 months; 2. Time to functional recovery(Study duration)

研究者

发起方
OrthoMediTec
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验